- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Castle Biosciences is a diagnostics & research business based in the US. Castle Biosciences shares (CSTL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $29.12 – a decrease of 6.64% over the previous week. Castle Biosciences employs 710 staff and has a trailing 12-month revenue of around $311.9 million.
What's in this guide?
Our top picks for where to buy Castle Biosciences stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
How to buy Castle Biosciences stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CSTL. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Castle Biosciences stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Castle Biosciences stock price (NASDAQ: CSTL)
Use our graph to track the performance of CSTL stocks over time.Castle Biosciences shares at a glance
Latest market close | $29.12 |
---|---|
52-week range | $16.97 - $35.84 |
50-day moving average | $31.22 |
200-day moving average | $25.36 |
Wall St. target price | $41.56 |
PE ratio | 140.381 |
Dividend yield | N/A |
Earnings per share (TTM) | $0.21 |
Is it a good time to buy Castle Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Castle Biosciences price performance over time
Historical closes compared with the close of $29.48 from 2024-12-11
1 week (2024-12-06) | -5.48% |
---|---|
1 month (2024-11-13) | -7.30% |
3 months (2024-09-13) | -5.45% |
6 months (2024-06-13) | 29.98% |
1 year (2023-12-13) | 43.45% |
---|---|
2 years (2022-12-13) | 23.50% |
3 years (2021-12-13) | 40.42 |
5 years (2019-12-13) | 29.5 |
Is Castle Biosciences stock undervalued or overvalued?
Valuing Castle Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Castle Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Castle Biosciences's P/E ratio
Castle Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 140x. In other words, Castle Biosciences shares trade at around 140x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Castle Biosciences's EBITDA
Castle Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12.4 million.
The EBITDA is a measure of a Castle Biosciences's overall financial performance and is widely used to measure a its profitability.
Castle Biosciences financials
Revenue TTM | $311.9 million |
---|---|
Operating margin TTM | 5.92% |
Gross profit TTM | $105 million |
Return on assets TTM | -0.14% |
Return on equity TTM | 1.47% |
Profit margin | 1.95% |
Book value | $15.77 |
Market Capitalization | $825.7 million |
TTM: trailing 12 months
Castle Biosciences share dividends
We're not expecting Castle Biosciences to pay a dividend over the next 12 months.
Castle Biosciences share price volatility
Over the last 12 months, Castle Biosciences's shares have ranged in value from as little as $16.965 up to $35.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Castle Biosciences's is 0.985. This would suggest that Castle Biosciences's shares are less volatile than average (for this exchange).
Castle Biosciences overview
Castle Biosciences, Inc. , a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. .
Frequently asked questions
nullWhat percentage of Castle Biosciences is owned by insiders or institutions?
Currently 3.213% of Castle Biosciences shares are held by insiders and 94.548% by institutions. How many people work for Castle Biosciences?
Latest data suggests 710 work at Castle Biosciences. When does the fiscal year end for Castle Biosciences?
Castle Biosciences's fiscal year ends in December. Where is Castle Biosciences based?
Castle Biosciences's address is: 505 South Friendswood Drive, Friendswood, TX, United States, 77546 What is Castle Biosciences's ISIN number?
Castle Biosciences's international securities identification number is: US14843C1053 What is Castle Biosciences's CUSIP number?
Castle Biosciences's Committee on Uniform Securities Identification Procedures number is: 14843C105
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to gift stock
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
-
Acorns review 2024
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.
Ask a question